MedTrace Logo

Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

NCT04238624 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-07-02

No results posted yet for this study

Summary

This study is being done to see if adding the study drug, cemiplimab, to the standard therapy with dabrafenib and trametinib is an effective treatment against anaplastic thyroid cancer.

Conditions

  • Anaplastic Thyroid Cancer
  • Thyroid Cancer
  • BRAF Gene Mutation
  • BRAF Mutation-Related Tumors

Interventions

DRUG

Dabrafenib

Participants will receive dabrafenib 150 mg orally twice a day

DRUG

Trametinib

Participants will receive trametinib 2 mg orally once a day

Sponsors & Collaborators

Principal Investigators

  • Eric Sherman, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-20
Primary Completion
2026-06-20
Completion
2026-06-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04238624 on ClinicalTrials.gov